Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): Results of the pan-american collaborative retina study group (PACORES)

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 246, Issue 1, 2008, Pages 81-87

  Wu, Lihteh ^a,h   Martínez Castellanos, María A ^b   Quiroz Mercado, Hugo ^b   Arevalo, J Fernando ^c   Berrocal, María H ^d   Farah, Michel E ^e   Maia, Mauricio ^e   Roca, José A ^f   Rodriguez, Francisco J ^g  

^a Instituto de Cirugia Ocular   (Costa Rica)

^b Asociacion para Evitar la Ceguera en Mexico IAP   (Mexico)

^c Clinica Oftalmologica Centre Caracas   (Venezuela)

^d UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f CLÍNICA RICARDO PALMA   (Peru)

^g Fundacion Oftalmologica Nacional   (Colombia)

^h NONE   (Costa Rica)

Author keywords

Age related macular degeneration; Angiogenesis; Choroidal neovascularization; Diabetic macular edema; Intravitreal bevacizumab; Proliferative diabetic retinopathy; Safety

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CORTICOSTEROID;

ADULT; ANEURYSM; ARTICLE; BACTERIUM CULTURE; BLOOD PRESSURE; CASE STUDY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; FOOT DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; SIDE EFFECT; SOUTH AND CENTRAL AMERICA; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; UVEITIS; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DIABETIC RETINOPATHY; FEMALE; HUMANS; INJECTIONS; MACULAR DEGENERATION; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETREATMENT; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 36448993366     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-007-0660-z     Document Type: Article

References (33)

1. Adamis AP, Aiello LP, D'Amato RA (1999) Angiogenesis and ophthalmic disease. Angiogenesis 3:9-14
2. Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111-118
3. Qaum T, Xu Q, Joussen AM, et al (2001) VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408-2413
4. Saishin Y, Saishin Y, Takahashi K, et al (2003) VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241-248
5. Cunningham ET Jr, Adamis AP, Altaweel M, et al (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:1747-1757
6. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816
7. Heier JS, Antoszyk AN, Pavan PR, et al (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study. Ophthalmology 113(642):e1-e4
8. Hurwitz H, Fehrenbacher L, Novotny W, et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
9. Michels S, Rosenfeld PJ, Puliafito CA, et al (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035-1047
10. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336-339
11. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331-335
12. Aiello LP, Brucker AJ, Chang S, et al (2004) Evolving guidelines for intravitreous injections. Retina 24:S3-19
13. Drolet DW, Nelson J, Tucker CE, et al (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17:1503-1510
14. Gaudreault J, Fei D, Rusit J, et al (2005) Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726-733
15. van Wijngaarden P, Coster DJ, Williams KA (2005) Inhibitors of ocular neovascularization: Promises and potential problems. JAMA 293:1509-1513
16. Sane DC, Anton L, Brosnihan KB (2004) Angiogenic growth factors and hypertension. Angiogenesis 7:193-201
17. Kernt M, Neubauer AS, Kampik A (2007) Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85:119-120
18. Ratner M (2004) Genentech discloses safety concerns over Avastin. Nat Biotechnol 22:1198
19. Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344-1349
20. Spaide RF, Laud K, Fine HF, et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383-390
21. Avery RL, Pieramici DJ, Rabena MD, et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3):363-372 e5
22. (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119:198-207
23. (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541-560
24. Slakter JS, Bochow TW, D'Amico DJ, et al (2006) Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 11:3-13
25. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19:361-372
26. Geiss LS, Herman WH, PJS (2007) Mortality in Non-Insulin Dependent Diabetes. Diabetes in America, 2nd Ed. http://diabetes.niddk.nih.gov/dm/ pubs/america/pdf/chapter11.pdf. Accessed February 14
27. Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257-261
28. Shahar J, Avery RL, Heilweil G, et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262-269
29. Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26:270-274
30. Luthra S, Narayanan R, Marques LE, et al (2006) Evaluation of in vitro effects of bevacizumab (avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26:512-518
31. Luke M, Warga M, Ziemssen F, et al (2006) Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 90:1178-1182
32. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr (2004) Risks of intravitreous injection: A comprehensive review. Retina 24:676-698
33. Ziemssen F, Warga M, Neuhann IM, et al (2006) Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function? Br J Ophthalmol 90:922